Mantomed (Memantine Hydrochloride)

Memantine is used in the management of Alzheimer’s disease, acting on the glutamatergic pathway to improve cognitive function.

• Alzheimer’s disease (mild to moderate): may help maintain memory and daily activities.
• Alzheimer’s disease (moderate to severe): can support functional abilities and slow decline.
• Behavioral symptoms of Alzheimer’s disease: may reduce agitation and improve overall patient behavior.

• Memantine hydrochloride acts as a non‑competitive antagonist at the NMDA (N‑methyl‑D‑aspartate) receptor. By binding to the receptor-associated ion channel, it reduces excessive calcium influx caused by glutamate over‑activation, thereby decreasing excitotoxic neuronal injury and supporting neuronal survival in Alzheimer’s disease.

Adverse reactions to memantine are reported across a range of frequencies.

Common Side Effects

• Dizziness: mild to moderate vertigo or light‑headedness.
• Headache: transient cranial pain.
• Constipation: reduced bowel movements.
• Confusion: occasional disorientation.
• Hypertension: elevated blood pressure readings.
• Insomnia: difficulty initiating or maintaining sleep.

Serious or Rare Side Effects

• Seizures: convulsive episodes requiring medical attention.
• Hallucinations: visual or auditory perceptual disturbances.
• Cardiac arrhythmia: irregular heart rhythm.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Suicidal thoughts: emergent ideation or behavior.
• Hepatic dysfunction: abnormal liver enzyme elevations.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor for adverse events.

• Renal impairment: adjust dose or monitor renal function.
• Hepatic impairment: use with caution in liver disease.
• Cardiovascular disease: monitor blood pressure and heart rate.
• Concomitant NMDA antagonists: avoid combined use due to additive effects.
• Pregnancy: safety not established; weigh potential benefits against risks.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Memantine may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Amantadine: additive NMDA antagonism may increase neurotoxicity.
• Ketamine: combined NMDA blockade can exacerbate central nervous system effects.
• Other NMDA receptor antagonists: risk of heightened adverse neurological reactions.

Moderate Interactions (Monitor Closely)

• Anticholinesterase inhibitors (e.g., donepezil): may require dose adjustment.
• Antihypertensive agents: monitor blood pressure for additive effects.
• Diuretics: watch for electrolyte disturbances.
• NSAIDs: increased risk of renal impairment.
• Antipsychotics: potential for enhanced central side effects.